Skip to Main Content

Paper Details

Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome.
Nat Commun
89
2017
-expressing cells, -treated, MDS, Mutant U2AF1, Mutant U2AF1-expressing cells, S34F, U2AF1, U2AF1 mutations, U2AF1(S34F), cells, haematological cancers, haematopoietic cells, haematopoietic progenitor cell, mice, mutant U2AF1, mutant U2AF1(, mutant cells, myelodysplastic syndromes, patients, pre-mRNA, primary patient cells, spliceosome gene mutations, spliceosome genes, sudemycin, sudemycin-treated mutant cells, sudemycins
Author NameAffiliation
Brian S WhiteWashington University School of Medicine
Robert S FultonMcDonnell Genome Institute, Washington University
Robert S FultonMcDonnell Genome Institute, Washington University
Catrina FronickMcDonnell Genome Institute, Washington University
Michelle O'LaughlinMcDonnell Genome Institute, Washington University
Timothy A GraubertMassachusetts General Hospital Cancer Center
Matthew J WalterWashington University School of Medicine
  • 1 - 7

Datasets

Release 1.2